ABSTRACT
CONTEXT: DNA methylation in the diagnosis of gestational diabetes. OBJECTIVE: To assess the value of DNA methylation in the diagnosis of gestational diabetes (GDM) and in the prediction of maternal postpartum glucose disturbances. METHODS: Two-stage observational study performed between July 2006 and December 2010, at University Hospital. Forty-eight randomly selected pregnant women formed the discovery cohort (24 with GDM and 24 controls) and 252 pregnant women (94 with GDM and 158 controls) formed the replication cohort. GDM women were re-evaluated 4 years postpartum. The main outcome measures were GDM, type 2 diabetes or prediabetes at 4 years postpartum. RESULTS: We identified 3 CpG sites related to LINC00917, TRAPPC9, and LEF1 that were differentially methylated in women with GDM and abnormal glucose tolerance; and sites associated with LINC00917 and TRAPPC9 were independently associated with an abnormal glucose tolerance status 4 years postpartum after controlling for clinical variables. Moreover, the site associated with LINC00917 and the combination of the 3 sites had the highest predictive values. CONCLUSION: Our results suggest that some of these sites may be implicated in the development of GDM and postpartum abnormal glucose tolerance.
Subject(s)
Diabetes Mellitus, Type 2 , Diabetes, Gestational , Glucose Intolerance , Blood Glucose , DNA Methylation , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/genetics , Diabetes, Gestational/diagnosis , Diabetes, Gestational/genetics , Female , Glucose , Glucose Intolerance/diagnosis , Glucose Intolerance/genetics , Glucose Tolerance Test , Humans , Postpartum Period , PregnancyABSTRACT
BACKGROUND/OBJECTIVES: To study whether FGF21 was present in cord blood and explore its relationship with maternal variables and postnatal growth. SUBJECTS AND METHODS: The study included 157 pregnant women at the beginning of the third trimester; 79 with gestational diabetes (GDM), 78 with normal glucose tolerance (NGT), and their offspring. Glucose metabolism was assessed by oral glucose tolerance test. Insulin resistance was assessed by homeostasis model assessment index-insulin resistance (HOMA-IR). FGF21 was determined in maternal plasma drawn at recruitment and in cord blood obtained at delivery. Offspring weight and height was assessed at birth and at 12, 24 and 48 months. RESULTS: Maternal FGF21 was higher in gestational diabetes than in the normal glucose-tolerant group, whereas similar cord blood FGF21 levels were observed in both groups. Lower cord blood FGF21 was strongly positively correlated with maternal circulating levels. This relationship was independent of mother's prepregnancy body mass index (BMI), glucose levels and HOMA-IR. Although maternal FGF21 levels were correlated with prepregnancy BMI and HOMA-IR index, no relationship was observed between FGF21 and birth weight. However, cord blood FGF21 levels were correlated with BMI Zeta Score at 12 and 24 months, and this relationship became stronger when only the NGT group was analyzed. CONCLUSION: FGF21 is present in human cord blood, and its levels are closely correlated with maternal levels. The association observed between cord blood FGF21 and postnatal BMI may suggest a potential role during intrauterine life that may influence future metabolic imbalance.
Subject(s)
Child Development/physiology , Diabetes, Gestational/blood , Fetal Blood/metabolism , Fibroblast Growth Factors/blood , Adult , Birth Weight/genetics , Body Mass Index , Child, Preschool , Diabetes, Gestational/genetics , Female , Fetal Blood/chemistry , Fibroblast Growth Factors/analysis , Fibroblast Growth Factors/genetics , Glucose Tolerance Test , Humans , Infant , Infant, Newborn , Male , Parturition/blood , Pregnancy , Pregnancy Trimester, Third/blood , Pregnancy Trimester, Third/geneticsABSTRACT
No disponible
